ATC Group: L01XL10 Nadofaragene firadenovec

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XL10 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XL Antineoplastic cell and gene therapy
5 L01XL10

Active ingredients in L01XL10

Active Ingredient

Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium. Intravesical instillation of nadofaragene firadenovec results in cell transduction and transient local expression of the IFNα2b protein that is anticipated to have anti-tumor effects.

Related product monographs

Document Type Information Source  
 ADSTILADRIN Suspension for intravesical instillation MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines